Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TWOPLUS-HD: Twice-Weekly vs Thrice-Weekly Hemodialysis Initiation
NCT03740048Phase 3Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jun 2019
- Primary completion
- Nov 2021
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in end stage renal disease (ESRD) (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Patients' Adherence to Study Protocol at 24 months. Started Jun 2019; status: completed.
02
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT03740048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03740048.